{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:52:34Z","timestamp":1790855554383,"version":"4.1.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:title>Graphical Abstract<\/jats:title><jats:p\/>","DOI":"10.3389\/fphar.2022.854965","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T08:32:12Z","timestamp":1669797132000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Novel 1,2,3-Triazole Erlotinib Derivatives as Potent IDO1 Inhibitors: Design, Drug-Target Interactions Prediction, Synthesis, Biological Evaluation, Molecular Docking and ADME Properties Studies"],"prefix":"10.3389","volume":"13","author":[{"given":"Gui-Qing","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Qing","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Ying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Zeng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Xue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long-Fei","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"15690","DOI":"10.1021\/ja076186k","article-title":"Human Tryptophan Dioxygenase: A Comparison to Indoleamine 2,3-dioxygenase","volume":"129","author":"Batabyal","year":"2007","journal-title":"J. Am. Chem. Soc."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.1016\/j.bmc.2019.07.005","article-title":"1,2,3-Triazole-containing Hybrids as Leads in Medicinal Chemistry: A Recent Overview","volume":"27","author":"Bozorov","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"B3","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/13543776.2018.1441290","article-title":"A Patent Review of Ido1 Inhibitors for Cancer","volume":"28","author":"Cheong","year":"2018","journal-title":"Expert Opin. Ther. Pat"},{"key":"B4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ejmech.2017.09.044","article-title":"Fragment-based Approach to Identify Ido1 Inhibitor Building Blocks","volume":"141","author":"Coletti","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"B5","doi-asserted-by":"publisher","first-page":"113631","DOI":"10.1016\/j.ejmech.2021.113631","article-title":"Design, Synthesis and Biological Evaluation of Exiguamine A Analogues as Ido1 Inhibitors","volume":"223","author":"Dong","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"B6","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3389\/fonc.2018.00370","article-title":"Indoximod: An Immunometabolic Adjuvant that Empowers T Cell Activity in Cancer","volume":"8","author":"Fox","year":"2018","journal-title":"Front. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"5545","DOI":"10.1093\/bioinformatics\/btaa1005","article-title":"DeepPurpose: A Deep Learning Library for Drug-Target Interaction Prediction","volume":"36","author":"Huang","year":"2020","journal-title":"Bioinformatics"},{"key":"B8","doi-asserted-by":"publisher","first-page":"9995","DOI":"10.1039\/d1ra00359c","article-title":"Biologically Guided Isolation and ADMET Profile of New Factor Xa Inhibitors from Glycyrrhiza Glabra Roots Using In Vitro and In Silico Approaches","volume":"11","author":"Ibrahim","year":"2021","journal-title":"RSC Adv."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1158\/1078-0432.CCR-18-2740","article-title":"Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (Ido1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors","volume":"25","author":"Jung","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3389\/fonc.2018.00423","article-title":"Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-dioxygenase 1 Inhibitors (Ido1) for Human Cancers","volume":"8","author":"Komiya","year":"2018","journal-title":"Front. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1182\/blood-2009-09-246124","article-title":"Selective Inhibition of Ido1 Effectively Regulates Mediators of Antitumor Immunity","volume":"115","author":"Liu","year":"2010","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1111\/bcp.13961","article-title":"Investigation of the Absolute Bioavailability and Human Mass Balance of Navoximod, a Novel Ido1 Inhibitor","volume":"85","author":"Ma","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.ejmech.2015.12.028","article-title":"O-alkylhydroxylamines as Rationally-Designed Mechanism-Based Inhibitors of Indoleamine 2,3-dioxygenase-1","volume":"108","author":"Malachowski","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"B14","doi-asserted-by":"publisher","first-page":"579024","DOI":"10.3389\/fphar.2020.579024","article-title":"Discovery of Icotinib-1,2,3-Triazole Derivatives as Ido1 Inhibitors","volume":"11","author":"Mao","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11912-018-0697-7","article-title":"Combination Immunotherapy in Non-small Cell Lung Cancer","volume":"20","author":"Marmarelis","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00281-018-0702-0","article-title":"Inhibiting Ido Pathways to Treat Cancer: Lessons from the ECHO-301 Trial and beyond","volume":"41","author":"Muller","year":"2019","journal-title":"Semin. Immunopathol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s40425-018-0351-9","article-title":"Phase Ia Study of the Indoleamine 2,3-dioxygenase 1 (Ido1) Inhibitor Navoximod (GDC-0919) in Patients with Recurrent Advanced Solid Tumors","volume":"6","author":"Nayak-Kapoor","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1073\/pnas.1719190115","article-title":"Immune-modulating Enzyme Indoleamine 2,3-dioxygenase Is Effectively Inhibited by Targeting its Apo-form","volume":"115","author":"Nelp","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"B19","doi-asserted-by":"publisher","first-page":"i821","DOI":"10.1093\/bioinformatics\/bty593","article-title":"DeepDTA: Deep Drug-Target Binding Affinity Prediction","volume":"34","author":"\u00d6zt\u00fcrk","year":"2018","journal-title":"Bioinformatics"},{"key":"B20","doi-asserted-by":"publisher","first-page":"6194","DOI":"10.1016\/j.bmc.2016.10.003","article-title":"Discovery and Preliminary Structure-Activity Relationship of 1H-Indazoles with Promising Indoleamine-2,3-Dioxygenase 1 (Ido1) Inhibition Properties","volume":"24","author":"Qian","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1002\/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4","article-title":"A Stepwise Huisgen Cycloaddition Process: Copper(I)-catalyzed Regioselective \"ligation\" of Azides and Terminal Alkynes","volume":"41","author":"Rostovtsev","year":"2002","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"B22","doi-asserted-by":"publisher","first-page":"98771","DOI":"10.18632\/oncotarget.21936","article-title":"Tyrosine Kinase Inhibitors Show Different Anti-brain Metastases Efficacy in NSCLC: A Direct Comparative Analysis of Icotinib, Gefitinib, and Erlotinib in a Nude Mouse Model","volume":"8","author":"Tan","year":"2017","journal-title":"Oncotarget"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1021\/acschemneuro.1c00399","article-title":"Virtual Screening and Biological Activity Evaluation of New Potent Inhibitors Targeting LRRK2 Kinase Domain","volume":"12","author":"Tan","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1021\/ml500247w","article-title":"Crystal Structures and Structure-Activity Relationships of Imidazothiazole Derivatives as Ido1 Inhibitors","volume":"5","author":"Tojo","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"B25","first-page":"127","article-title":"Molecular Docking and Admet Analysis of Synthetic Statins for Hmg-Coa Reductase Inhibition Activity","volume":"58","author":"Toppo","year":"2021","journal-title":"Indian J. Biochem. Biophys."},{"key":"B26","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.arabjc.2011.10.007","article-title":"Molecular Docking Studies of Some New Imidazole Derivatives for Antimicrobial Properties","volume":"6","author":"Vijesh","year":"2013","journal-title":"Arabian J. Chem."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1039\/c9md00208a","article-title":"Recent Advances in the Discovery of Indoleamine 2,3-dioxygenase 1 (Ido1) Inhibitors","volume":"10","author":"Wang","year":"2019","journal-title":"MedChemComm"},{"key":"B28","doi-asserted-by":"publisher","first-page":"128373","DOI":"10.1016\/j.bmcl.2021.128373","article-title":"Discovery of Novel Ido1 Inhibitors Targeting the Protein's Apo Form through Scaffold Hopping from holo-Ido1 Inhibitor","volume":"52","author":"Wu","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B29","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3892\/mco.2016.956","article-title":"Comparison of the Efficacy of Icotinib in Patients with Non-small-cell Lung Cancer According to the Type of Epidermal Growth Factor Receptor Mutation","volume":"5","author":"Xue","year":"2016","journal-title":"Mol. Clin. Oncol."},{"key":"B30","volume-title":"An Ido Inhibitor Containing NH-1,2,3-triazole and a Preparation Method Thereof","author":"Yang","year":"2013"},{"key":"B31","doi-asserted-by":"publisher","first-page":"7364","DOI":"10.1021\/jm900518f","article-title":"Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-dioxygenase with In Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model","volume":"52","author":"Yue","year":"2009","journal-title":"J. Med. Chem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1021\/acsmedchemlett.6b00391","article-title":"INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-Dioxygenase 1 (Ido1) Inhibitor for Immuno-Oncology","volume":"8","author":"Yue","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"B33","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/cmi.2017.143","article-title":"Ido1 in Cancer: a Gemini of Immune Checkpoints","volume":"15","author":"Zhai","year":"2018","journal-title":"Cell Mol Immunol"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.854965\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T08:32:16Z","timestamp":1669797136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.854965\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,23]]},"references-count":33,"alternative-id":["10.3389\/fphar.2022.854965"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.854965","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,23]]},"article-number":"854965"}}